PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för dordaviprone. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

22 hits

Bibliografisk träff 2024-10-18

Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS.

Mol Cancer · published erratum; correction · DOI 10.1186/s12943-024-02158-w

Bibliografisk träff 2024-08-22

Discovery of Dehydrogenated Imipridone Derivatives as Activators of Human Caseinolytic Protease P.

Jiang J, Xie G, Li T, Ding H, Tang R, Luo J, Li Q, Lu W, Xiao Y, Sun H.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.4c00798

Bibliografisk träff 2024-08-07

Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201.

Hansford JR, Bouche G, Ramaswamy V, Jabado N, Fonseca A, Moloney S, Gottardo NG, Robinson GW, Gajjar A, Tinkle CL, Fisher PG, Foreman N, Ashley DM, Ziegler DS, Eisenstat DD, Massimino M, Witt O, Bartels U, Rutkowski S, Hargrave D, Fouladi M, Pfister SM, Bouffet E.

J Clin Oncol · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1200/jco.24.00709

Bibliografisk träff 2024-08-01

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

de la Nava D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, Lacalle A, Casares N, Zalacain M, Marrodan L, García-Moure M, Ochoa MC, Tallon-Cobos AC, Hernandez-Osuna R, Marco-Sanz J, Dhandapani L, Hervás-Corpión I, Becher OJ, Nazarian J, Mueller S, Phoenix TN, van der Lugt J, Hernaez M, Guruceaga E, Koschmann C, Venneti S, Allen JE, Dun MD, Fueyo J, Gomez-Manzano C, Gallego Perez-Larraya J, Patiño-García A, Labiano S, Alonso MM.

Neuro Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/neuonc/noae066

Bibliografisk träff 2024-06-01

Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.

Arrillaga-Romany I, Miller JJ.

Neuro Oncol · editorial; comment; journal article · DOI 10.1093/neuonc/noae051

Bibliografisk träff 2024-05-15

Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.

Zhang Y, Tapinos N, Lulla R, El-Deiry WS.

Am J Cancer Res · research-article; journal article · DOI 10.62347/zotv8006

Bibliografisk träff 2024-05-01

A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.

Jackson ER, Persson ML, Fish CJ, Findlay IJ, Mueller S, Nazarian J, Hulleman E, van der Lugt J, Duchatel RJ, Dun MD.

Neuro Oncol · research support, non-u.s. gov't; review-article; review; journal article; research support, n.i.h., extramural · DOI 10.1093/neuonc/noad144

Bibliografisk träff 2024-05-01

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.

Odia Y, Hall MD, Cloughesy TF, Wen PY, Arrillaga-Romany I, Daghistani D, Mehta MP, Tarapore RS, Ramage SC, Allen JE.

Neuro Oncol · research support, non-u.s. gov't; review-article; journal article; research support, n.i.h., extramural · DOI 10.1093/neuonc/noae021

Bibliografisk träff 2024-05-01

Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.

Odia Y, Koschmann C, Vitanza NA, de Blank P, Aguilera D, Allen J, Daghistani D, Hall M, Khatib Z, Kline C, MacDonald T, Mueller S, Faison SL, Allen JE, Naderer OJ, Ramage SC, Tarapore RS, McGovern SL, Khatua S, Zaky W, Gardner SL.

Neuro Oncol · research support, non-u.s. gov't; multicenter study; review-article; clinical trial, phase i; journal article · DOI 10.1093/neuonc/noae001

Bibliografisk träff 2024-05-01

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.

Arrillaga-Romany I, Lassman A, McGovern SL, Mueller S, Nabors B, van den Bent M, Vogelbaum MA, Allen JE, Melemed AS, Tarapore RS, Wen PY, Cloughesy T.

Neuro Oncol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; review-article; randomized controlled trial; journal article · DOI 10.1093/neuonc/noae031

Bibliografisk träff 2024-04-01

Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.

Xin DE, Liao Y, Rao R, Ogurek S, Sengupta S, Xin M, Bayat AE, Seibel WL, Graham RT, Koschmann C, Lu QR.

Neuro Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/neuonc/noad222

Bibliografisk träff 2024-02-09

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.

Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn LB, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore RS, Taylor L, Umemura Y, Wen PY.

J Clin Oncol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1200/jco.23.01134

Bibliografisk träff 2023-12-15

ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.

Parker CS, Zhou L, Prabhu VV, Lee S, Miner TJ, Ross EA, El-Deiry WS.

Am J Cancer Res · research-article; journal article

Bibliografisk träff 2023-10-01

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.

Atkins SLP, Greer YE, Jenkins S, Gatti-Mays ME, Houston N, Lee S, Lee MJ, Rastogi S, Sato N, Burks C, Annunziata CM, Lee JM, Nagashima K, Trepel JB, Lipkowitz S, Zimmer AS.

Oncologist · clinical trial, phase ii; research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/oncolo/oyad164

Bibliografisk träff 2023-09-29

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer.

Farmaki E, Nath A, Emond R, Karimi KL, Grolmusz VK, Cosgrove PA, Bild AH.

Elife · research-article; journal article; research support, n.i.h., extramural · DOI 10.7554/elife.85898

Bibliografisk träff 2023-08-01

[Inhibitory Effect of Small Molecule Compound TIC10 on Leukemia].

Chen T, Li L, Chen Z, Hou Y.

Zhongguo Shi Yan Xue Ye Xue Za Zhi · journal article; english abstract · DOI 10.19746/j.cnki.issn.1009-2137.2023.05.005

Bibliografisk träff 2023-01-13

Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma.

Granau AM, Andersen PA, Jakobsen T, Taouxi K, Dalila N, Mogensen JB, Kristensen LS, Grønbæk K, Dimopoulos K.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers15020510

Bibliografisk träff 2022-12-08

ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL.

Mishukov A, Odinokova I, Mndlyan E, Kobyakova M, Abdullaev S, Zhalimov V, Glukhova X, Galat V, Galat Y, Senotov A, Fadeev R, Artykov A, Gasparian ME, Solovieva M, Beletsky I, Holmuhamedov E.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms232415551

Bibliografisk träff 2022-05-15

Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the Apc min/+ mouse model.

Madka V, De La Cruz A, Pathuri G, Panneerselvam J, Zhang Y, Stratton N, Hacking S, Finnberg NK, Safran HP, Sei S, Glaze ER, Shoemaker R, Fox JT, Raufi AG, El-Deiry WS, Rao CV.

Am J Cancer Res · research-article; journal article

Bibliografisk träff 2022-05-01

Neuroendocrine and Rare Tumor Advances: A New and Promising TRAIL Emerges.

Owen DH, Trikalinos NA.

Clin Cancer Res · article-commentary; comment; editorial · DOI 10.1158/1078-0432.ccr-22-0120

Bibliografisk träff 2022-02-15

Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).

Liguori NR, Sanchez Sevilla Uruchurtu A, Zhang L, Abbas AE, Lee YS, Zhou L, Azzoli CG, El-Deiry WS.

Am J Cancer Res · research-article; journal article

Bibliografisk träff 2021-11-26

ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression.

Dwucet A, Pruss M, Cao Q, Tanriover M, Prabhu VV, Allen JE, Peraud A, Westhoff MA, Siegelin MD, Wirtz CR, Karpel-Massler G.

Front Cell Dev Biol · research-article; journal article · DOI 10.3389/fcell.2021.734699

Go to research.

Publications in the selection

Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Discovery of Dehydrogenated Imipridone Derivatives as Activators of Human Caseinolytic Protease P.

Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201.

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.

Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.

A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.

Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.

Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.

ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer.

[Inhibitory Effect of Small Molecule Compound TIC10 on Leukemia].

Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma.

ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL.

Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the <i>Apc</i> <sup>min/+</sup> mouse model.

Neuroendocrine and Rare Tumor Advances: A New and Promising TRAIL Emerges.

Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).

ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells <i>in Vitro</i> Independent of C-Myc Expression.